Dosing EvaLuation of Tenofovir Alafenamide on Epstein-Barr Virus (The DELTA-EBV study)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522781-77-01

Enrollment

Registered

2026-05-28

Start date

Unknown

Completion date

Unknown

Last updated

2026-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epstein-Barr virus infection

Brief summary

Number of participants experiencing treatment-emergent adverse events (AEs).

Detailed description

Within-participants changes in EBV shedding frequency in saliva, defined as number of samples with detectable levels of EBV during sequential dose escalation., Within-participant changes in EBV viral load in saliva during sequential dose escalation., Within-participant changes in EBV specific CD4 T cells by ELISPOT assay during sequential dose escalation., Within-participant changes in IgG antibodies to EBNA1 and VCA during sequential dose escalation., Secondary safety endpoints related to the IMP

Interventions

DRUGVemlidy 25 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Number of participants experiencing treatment-emergent adverse events (AEs).	—

Secondary

Measure	Time frame
Within-participants changes in EBV shedding frequency in saliva, defined as number of samples with detectable levels of EBV during sequential dose escalation., Within-participant changes in EBV viral load in saliva during sequential dose escalation., Within-participant changes in EBV specific CD4 T cells by ELISPOT assay during sequential dose escalation., Within-participant changes in IgG antibodies to EBNA1 and VCA during sequential dose escalation., Secondary safety endpoints related to the IMP	—

Measure

Time frame

—

Outcome results

None listed

Source: EU CTIS · Data processed: May 29, 2026